Un extraño caso de infarto de miocardio

Referencias
1. Kardasz I, De Caterina R. Myocardial infarction with normal coronary arteries: a conundrum with multiple aetiologies and variable prognosis: an update. J Intern Med 2007;261:330-48.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22:14-22.
3. Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders.  Blood Rev 2010;24:227-32.
4. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008; 22:2020-8.
5. Barbui T. How to manage thrombosis in myeloproliferative neoplasms. Curr Opin
Oncol 2011; 23:654-8.
6. Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115:778-82.
7. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114-24.
8. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;
355:2452-66.
9. Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management  of  adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149:352-75.
10. Schafer AI. Thrombocytosis. N Engl J Med 2004; 350:1211-9.
11. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29:3179-84.
12. Marchioli R, Finazzi G, Specchia G, et inal. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.
13. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87:285-93.
14. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366:799-807.
15. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366:787-98.
16. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev 2011; 25:229-37.